Categories
Life Style

I fell out of love with the lab, and in love with business

[ad_1]

Portrait of Karolina Makovskytė.

Karolina Makovskytė is head of business development at the firm Caszyme, which specializes in CRISPR-based molecular tools.Credit: Caszyme, LLC archive

Voices from Lithuania

In May, Lithuania marks 20 years of European Union membership. The Baltic country is keen to develop its global presence in the life sciences and biotechnology sectors by retaining home-grown talent, persuading scientists working abroad to return to the country, and attracting researchers from other nations. Nature spoke to three researchers who have chosen to develop their careers in Lithuania. Here, Nature speaks to Karolina Makovskytė, head of business development at Caszyme, a biotechnology firm that specializes in CRISPR-based molecular tools.

Before the COVID-19 pandemic, when I was an undergraduate molecular-biology student at Vilnius University in Lithuania, I loved laboratory work. But when labs closed during the pandemic, I lost my motivation and it never returned.

In 2021, during the fourth and final year of my degree, a recruiter contacted me about a part-time junior product-manager post at the Vilnius site of biotechnology firm Thermo Fisher Scientific. The company was manufacturing reagents for messenger RNA vaccines, and it had built a whole new facility and was producing them on a large scale.

Thermo arrived in the country in 2010, when it acquired Lithuanian biotech company Fermentas for US$260 million. Its Vilnius site manufactures products for the life-science market, specifically molecular, protein and cellular-biology products. It also has a research and development centre.

It’s common for science students to work during their studies and for me it provided a chance to see what working in the biotech field was like, and to find out what options I had with a life-sciences degree, other than working in the laboratory.

I was working on a portfolio of nucleic-acid therapeutics, helping senior product managers with requests from companies for different nucleotides and enzymes, mainly for mRNA vaccine development and production. I carried on working at Thermo, during my master’s degree in molecular biotechnology, also at Vilnius University. Even on the administrative and business side, many people had a master’s or PhD.

As part of my master’s, I attended lectures on the genome-editing tool CRISPR, led by Giedrius Gasiūnas, co-founder and chief scientific officer at biotech company Caszyme in Vilnius.

Virginijus Šikšnys, another co-founder and chair of the management board, is a department head at Vilnius University’s Institute of Biotechnology. This demonstrates the blended nature of academia and the world of biotech start-up companies in Lithuania.

I applied for a business-development manager role there and started work in March 2022, while doing my master’s degree, which I completed last year. My job involves relationship building and representing the company abroad.

The company discovers and develops CRISPR-based molecular tools for diverse applications. It has 17 scientists and is growing all the time. In January, we moved premises to a larger building opposite the Vilnius site of the firm Northway Biotech, and close to Vilnius University Hospital.

Currently, Caszyme focuses on three elements. The first is research: finding new CRISPR–Cas nucleases for companies that are looking for specific characteristics. Second is licences: the company has a platform of nucleases that it has already identified, and it offers licences for further development. And third is analysis: Caszyme helps companies with expression, purification and biochemical analysis of Cas nucleases.

Currently, the firm has a handful of active collaborations in the therapeutics and diagnostics fields, including in infectious diseases and agriculture.

A friendly and close community

I think there are many aspects of academia and industry that set Lithuania apart from other countries. First, we have great universities that prepare scientists very well for the future. Scientists leave with not only theoretical knowledge, but also research experience working in a lab.

Lab work being done at Caszyme in Lithuania.

Karolina Makovskytė moved into industry after discovering the lab was not for her.Credit: Caszyme, LLC archive

Second is that the ecosystem is not a big one. It’s very easy to get to know most people and that’s an advantage because it makes collaborations easier.

Third, industry scientists have close contact with government institutions that ask us what businesses want and how they can help. I don’t want to say it’s easy to build a biotechnology company, but Lithuania has all the right tools to do high-quality research.

My proudest achievement is probably my personal growth. I can really see a difference between now and when I started working — I’ve gained knowledge and experience, and matured as a person. Last June, aged 25, I was promoted to head of business development.

I work remotely in Kaunas, the second-largest city in Lithuania, which has a beautiful old town and is known for its art deco architecture. We have three international airports and Vilnius is only an hour and a half by road, so it’s easy to get to the office when I need to. Some of my time is spent abroad — I’ve just come back from a technology summit in San Francisco, California, and now I’m in Rome.

I don’t want to work abroad permanently. Lithuania has wonderful countryside and is full of culture, too. Every year, in March we have an international film festival, which I have worked for as a volunteer in the past.

If you find you don’t like working in a lab, like me, my advice would be to find a job outside the lab and see if it fits. If it doesn’t, try something else and talk to people who have different positions in life sciences. Explore the opportunities.

I talk to lots of people at events and many of them have PhDs or have worked as postdocs but have decided that they don’t want to be scientists. There’s nothing shameful in that. People who work in business development or operations and who have a scientific degree are essential, too.

My advice for young scientists who are considering a research position in Lithuania is to just do it. We have a friendly and close research community so it’s very easy to collaborate. Also, scientists here have a wide network all over the world. It’s very easy to join projects that Lithuanian scientists are doing with global institutes and companies. We Lithuanians talk to each other a lot!

Jacqui Thornton’s travel and accommodation were provided by Go Vilnius, a development agency.

This interview has been edited for length and clarity.

This article is part of Nature Spotlight: Lithuania, an editorially independent supplement. Advertisers have no influence over the content.

[ad_2]

Source Article Link

Categories
News

Apple’s iPhone Shipments in China Fell 33% Last Month

[ad_1]

Apple’s iPhone shipments in China dropped by 33% in February compared to the same month last year, according to governement figures (via Bloomberg).

iphone 15 china
A report from China’s Academy of Information and Communications Technology showed that foreign brands shipped around 2.4 million smartphones last month. Given that Apple is the only overseas vendor with a meaningful market share, the company accounts for the vast majority of those shipments.

The decline in February marks the third consecutive month of lower iPhone shipments. Apple in January shipped some 5.5 million units in China, which is around 39% fewer handsets than the same time last year. In December, the company suffered a 30% year-on-year decline in the country.

Apple appears to be facing an uphill battle to reverse falling iPhone sales in China, with a 24% year-on-year decline in 2023 projected to deepen through 2024. Apple resellers in China have been increasingly dependent on discounts to shift ‌iPhone 15‌ stock. The discounts followed Apple’s own rare price reductions on its website ahead of the Lunar New Year holiday in February.

Apple’s efforts to counter the slump are also likely to be hampered by China’s decision last year to ban iPhones from the offices of multiple government agencies and state companies. China has a huge number of state-owned enterprises in power generation, seaport construction, mining, manufacturing, education, and investment markets.

Apple is also having to contend with strong interest in Huawei’s latest home-grown Mate 60 lineup, which was released in September just weeks before the iPhone 15 launched. Huawei’s Mate 60 Pro uses a new China-made 7-nanometer processor tailored for the local market, showcasing the kind of advanced semiconductor manufacturing capabilities that US sanctions were originally designed to prevent.

The overall Chinese smartphone market contracted by almost a third in February, according to research firm Canalys. Analysts still predict growth over the course of the year, but expect iPhone 15 sales to keep falling while local rivals continue to aggressively promote AI features in device marketing. CEO Tim Cook visited China earlier this month to Apple’s newest store in Shanghai and attend the China Development Forum in Beijing, where he said the country was “critical” to Apple.

[ad_2]

Source Article Link